期刊文献+

治疗慢性丙型肝炎新药Sofosbuvir 被引量:2

A New Drug for Chronic Hepatitis:C-Sofosbuvir
下载PDF
导出
摘要 鉴于丙型肝炎病毒(HCV)感染全球高发趋势,目前治疗方案因禁忌、严重不良反应等导致其使用的局限性,因此需要一种更有效、安全、简便、不适宜干扰素治疗的治疗药物。Sofosbuvir是具有这些特性的直接抗病毒药物,为HCV NS5 B聚合酶的尿苷核苷酸类似物抑制药,可有效对抗多种基因型HCV感染,具有良好的安全性和耐受性。本文综述Sofosbuvir的作用机制、药动学、不良反应、药物相互作用及临床试验。 In view of the high incidence trend of chronic hepatitis C virus infection in globe and the limitations caused by contraindication and severe adverse reactions of the treatment regimens,one kind of medicine with higher efficacy,safety and convenience is in urgent need for the interferon-free treatment of patients with chronic hepatitis C virus infection.Sofosbuvir is a direct antiviral agent with the above advantages.It is a pyrimidine nucleotide analog inhibitor for hepatitis C virus (HCV) NS5B polymerase,and exhibits potent antiviral activity against several hepatitis C virus genotypes with promising safety and tolerance.The action mechanisms,pharmacokinetics,adverse reactions,drug interactions and clinical study of sofosbuvir were introduced in this paper.
机构地区 开滦总医院
出处 《中国药师》 CAS 2014年第7期1224-1226,共3页 China Pharmacist
关键词 Sofosbuvir 丙型肝炎病毒 药理学 药动学 临床试验 药品不良反应 Sofosbuvir HCV Pharmacology Pharmacokinetics Clinical trials Drug adverse reactions
  • 相关文献

同被引文献34

  • 1Bota S, Sporea I, Popescu A,et al. Response to standard of care an- tiviral treatment in patients with HCV liver cirrhosis- a systematic re- view[ J]. J Gastrointestin Liver Dis,2011,20(3 ) :293-298.
  • 2Jacobson IM, McHutchison JG, Dusheko G. Telaprevir for previously untreated chronic hepatitis C virus infection [ J ]. N Engl J Med, 2011,364 ( 25 ) :2405-2416.
  • 3Zeuzem S, Andreone P, Pal S. Telaprevir for retreatment of HCV in- fection[J]. N Engl J Med,2011,364( 25 ) :2417-2428.
  • 4Poordad F, MeCone J, Bacon BR, et al. Boceprevir for untreated chronic HCV genotype 1 infection [ J ]. N Engl J Med, 2011,364 ( 13 ) : 1195-1206.
  • 5Bacon BR, Gordon SC, Lawitz E, et al. Boceprevir for previously treated chronic HCV Genotype 1 infection [ J ]. N Engl J Med, 2011, 364 ( 13 ) : 1207-1217.
  • 6Colombo M, Fernandez I, Abdurakhmanov D, et al. Safety and on- treatment efficacy of telaprevir: the early access program for patients with advanced hepatitis [ J ]. Gut, 2014, 63 (7) : 1150-1158.
  • 7Talwani R, Heil E, Gilliam B, et al. Simeprevir: A maerocyclic hey protease inhibitor[ J]. Drugs Today,2013,49 (12) :769-779.
  • 8Jacobson IM, Dore GJ, Foster GR, et al. Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chron- ic hepatitis C virus genotype 1 infection ( QUEST-1 ) : a phase 3, ran- domized, double-blind, placebo-controlled trial[J]. Lancet, 2014, 384(9941 ) :403-413.
  • 9Manus M, Marcellin P, Poordad F, et al. Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection(QUEST-2) : a random- ized, double-blind, placebo-controlled phase 3 trial [ J ]. Lancet, 2014, 384(9941 ) :414-426.
  • 10Forns X, Lawitz E, Zeuzem S, et al. Simeprevir with peginterferonand ribavirin leads to high rates of SVR in patients with HCV geno- type 1 who replased after previous therapy: a phase trial [ J ]. Gastro- enterology, 2014, 146 (7) : 1669-1679.

引证文献2

二级引证文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部